Department of General, Visceral and Transplant Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany.
J Clin Oncol. 2012 Jan 1;30(1):60-70. doi: 10.1200/JCO.2011.36.9504. Epub 2011 Nov 28.
Up to 25% of patients with node-negative colorectal cancer (CRC) on conventional histopathologic analysis ultimately die of recurrent disease. We performed a systematic review with meta-analyses to clarify whether molecular detection of isolated tumor cells or micrometastases in regional lymph nodes indicates high risk of disease recurrence and poor survival in node-negative CRC.
The following databases were searched in August 2011 to identify studies on the prognostic significance of molecular tumor-cell detection in regional lymph nodes of node-negative CRC: MEDLINE, BIOSIS, Science Citation Index, EMBASE, CCMed, and publisher databases. We extracted hazard ratios (HRs) and associated 95% CIs from the identified studies and performed random-effects model meta-analyses on overall survival, disease-specific survival, and disease-free survival.
A total of 39 studies with a cumulative sample size of 4,087 patients were included. Immunohistochemistry, reverse transcriptase polymerase chain reaction, and both techniques were applied in 30, seven, and two studies, respectively. Thirteen studies were graded with low risk of bias. Meta-analyses revealed that molecular tumor-cell detection in regional lymph nodes was associated with poor overall survival (HR, 2.20; 95% CI, 1.43 to 3.40), disease-specific survival (HR, 3.37; 95% CI, 2.31 to 4.93), and disease-free survival (HR, 2.24; 95% CI, 1.57-3.20). Subgroup analyses showed the prognostic significance of molecular tumor-cell detection of being independent of the applied detection method, molecular target, and number of retrieved lymph nodes.
Molecular detection of occult disease in regional lymph nodes is associated with an increased risk of disease recurrence and poor survival in patients with node-negative CRC.
在常规组织病理学分析中,多达 25%的淋巴结阴性结直肠癌(CRC)患者最终死于疾病复发。我们进行了系统评价和荟萃分析,以明确区域淋巴结中孤立肿瘤细胞或微转移的分子检测是否预示着淋巴结阴性 CRC 患者疾病复发风险增加和生存不良。
我们于 2011 年 8 月检索了以下数据库,以确定关于淋巴结阴性 CRC 区域淋巴结中分子肿瘤细胞检测的预后意义的研究:MEDLINE、BIOSIS、科学引文索引、EMBASE、CCMed 和出版商数据库。我们从确定的研究中提取了总生存率、疾病特异性生存率和无病生存率的风险比(HR)和相关 95%置信区间(CI),并进行了随机效应模型荟萃分析。
共纳入 39 项研究,累计样本量为 4087 例。免疫组织化学、逆转录聚合酶链反应和两种技术分别应用于 30、7 和 2 项研究。13 项研究的偏倚风险较低。荟萃分析显示,区域淋巴结中分子肿瘤细胞的检测与总生存率不良(HR,2.20;95%CI,1.43 至 3.40)、疾病特异性生存率(HR,3.37;95%CI,2.31 至 4.93)和无病生存率(HR,2.24;95%CI,1.57 至 3.20)相关。亚组分析表明,分子肿瘤细胞检测的预后意义与所应用的检测方法、分子靶标和所检出的淋巴结数量无关。
区域淋巴结隐匿性疾病的分子检测与淋巴结阴性 CRC 患者疾病复发风险增加和生存不良相关。